Academic Journals Database
Disseminating quality controlled scientific knowledge

Current and emerging treatments for the management of myasthenia gravis

Author(s): Sathasivam S

Journal: Therapeutics and Clinical Risk Management
ISSN 1176-6336

Volume: 2011;
Issue: default;
Start page: 313;
Date: 2011;
Original page

Sivakumar SathasivamThe Walton Centre NHS Foundation Trust, Lower Lane, Liverpool, UKAbstract: Myasthenia gravis is an autoimmune neuromuscular disorder. There are several treatment options, including symptomatic treatment (acetylcholinesterase inhibitors), short-term immunosuppression (corticosteroids), long-term immunosuppression (azathioprine, cyclosporine, cyclophosphamide, methotrexate, mycophenolate mofetil, rituximab, tacrolimus), rapid acting short-term immunomodulation (intravenous immunoglobulin, plasma exchange), and long-term immunomodulation (thymectomy). This review explores in detail these different treatment options. Potential future treatments are also discussed.Keywords: acetylcholinesterase inhibition, immunosuppression, immunomodulation, thymectomy
Save time & money - Smart Internet Solutions     

Tango Jona
Tangokurs Rapperswil-Jona